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Objective. We investigated whether the concentration of the glycoprotein fetuin A is altered in the second trimester amniotic fluid of
trisomy 21 pregnancies compared with euploid pregnancies. Methods. 25 pregnancies with an extra chromosome 21 were matched
for maternal and gestational age with 25 pregnancies with normal karyotype. Levels of fetuin A in amniotic fluid were measured
by a commercially available enzyme-linked immunosorbent assay (ELISA) kit. Results. The median concentration of fetuin A in
amniotic fluid of trisomy 21 pregnancies (5.3 ng/ml) was statistically significantly lower (P value = 0.008) compared with that
in euploid pregnancies (6.8 ng/mL). Conclusion. Lower levels of fetuin A in trisomy 21 may indicate an association with altered
metabolic pathways in this early stage that could potentially be associated with features of the syndrome, such as growth restriction
or impaired osteogenesis.
1. Introduction
Down’s syndrome (DS) occurs in about one out of every 500
to 1000 live births [1]. The majority of the cases result from
an extra copy of human chromosome 21, while the remain-
der are due to mosaicism or an extra part of chromosome
21. The phenotypic characteristics of DS vary significantly
among individuals. Features such as short stature, reduced
growth velocity [2], and reduced bone density [3] have been
described in fetuses, children, and adults with DS.
Fetuin A, also known as alpha-2-HS (Heremans-Schmid)
glycoprotein, is mainly expressed in the liver, the tongue and
placenta in humans [4]. It occurs in high serum and amniotic
fluid concentrations during fetal life [5] and is involved in
development-associated regulation of calcium metabolism
and osteogenesis [6]. It also accumulates in bones and teeth
as a major fraction of noncollagenous bone proteins [7].
Fetuin A also plays a positive role in insulin resistance in
humans and is associated with metabolic syndrome [8, 9].
We investigated whether altered concentration of fetuin
A is present in the second trimester in pregnancies with
trisomy 21 (DS) in order to elucidate the presence of possible
metabolic pathways in utero. We hypothesized that levels of
fetuin A in amniotic fluid might differ between pregnancies
with DS and euploid pregnancies and that presence or
absence of features in the DS group may potentially be
associated with the metabolic actions of fetuin A. Fetuin A,
which has been studied in maternal serum as a potential
novel marker in prenatal diagnosis of trisomy 21 in the first
trimester, has not been found to differ significantly in levels
between euploid and aneuploid pregnancies [10]. The focus
of our study is to elucidate a number of metabolic pathways
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Table 1: Descriptive characteristics of women (mean (standard de-
viation)) and levels (median (25th–75th percentile)) of fetuin A ac-
cording to fetal status (trisomy 21 or euploid).
Trisomy 21 fetuses, n = 25 Controls, n = 25
Maternal age (years) 35.9 (5.2) 34.9 (5.1)
Gestation (weeks) 19.3 (3.1) 18.4 (1.6)
Fetuin A (ng/mL) 5.3 (4.3–6.4) 6.8 (5.1–8.7)
in trisomy 21 rather than add new information to the already
studied field of prenatal diagnosis.
2. Methods
The study was set up in a university hospital, a private hospi-
tal, and a genetic center. Amniotic fluid samples were col-
lected from women who underwent amniocentesis in the
second trimester of pregnancy because of advanced maternal
age, pathological sonographic features, family history of
inherited disorders, or abnormal first trimester biochemical
screening for DS. Gestational age was estimated by an early
booking scan. Multiple pregnancies and pregnancies with
fetuses with gross anatomical abnormalities were excluded.
Fetal karyotype was checked by QF-PCR (quantitative fluo-
rescent polymerase chain reaction) analysis and confirmed
via conventional cytogenetic cultures.
Twenty-five pregnancies having a single fetus with an
extra chromosome 21 were identified and matched for ma-
ternal and gestational age with 25 uncomplicated singleton
pregnancies with normal karyotype that were delivered at
term. The Ethical Committee of the University Hospital
approved the study protocol. Written informed consent was
obtained from the participants.
Samples of amniotic fluid were centrifuged, and super-
natants were stored in polypropylene tubes at −80◦ Celsius
until the date of quantitative determination of fetuin A. Lev-
els of total fetuin A in the amniotic fluid were measured by a
commercially available enzyme-linked immunosorbent assay
(ELISA) kit (BioVendor-Laboratorni medicina a.s.). The sen-
sitivity, intra-assay and inter-assay coefficient of variation for
fetuin A were 0.35 ng/mL, 3.5%, and 5.4%, respectively. Ana-
lysts were blinded to the clinical information.
For the statistical analysis, we applied the nonparametric
Mann-Whitney test for the comparison of the fetuin A levels
between the two groups, since the measured hormone was
not normally distributed.
3. Results
Table 1 presents characteristics of the women as well as the
distribution of fetuin A according to the fetuses status. Age
and gestational week were similar between the two groups
(P = 0.513, P = 0.216, resp.), although women that car-
ried a fetus with trisomy 21 were slightly older and had the
amniocentesis at a later stage. More specifically, 80% of
the women with a DS fetus were under 40 years of age as
opposed to 90% of women with euploid fetuses. The median
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Figure 1: Scatter-plot graph of fetuin A concentrations (ng/mL) in
normal fetuses and fetuses with trisomy 21.
levels of fetuin A in cases with trisomy 21 were 5.3 ng/mL
as compared with 6.8 ng/mL in controls. Fetuin A was
statistically significantly (P = 0.008 from the Mann-Whitney
test) higher in amniotic fluid from euploid pregnancies
compared with the levels from pregnancies with fetuses
with DS. Figure 1 presents the concentrations of fetuin A
in amniotic fluid from euploid and trisomy 21 pregnancies
plotted against individual patients. In addition, gestational
age is correlated with fetuin A; the more advanced the
gestation, the higher the concentration of the hormone in
amniotic fluid for both groups (r = 0.44, P = 0.029 for
euploid pregnancies and r = 0.55, P = 0.005 for DS
pregnancies). On the other hand, its levels are not correlated
with maternal age (P = 0.42). There is a considerable overlap
during the early second trimester in the levels of fetuin A in
amniotic fluid between euploid and trisomy 21 pregnancies,
but this becomes less apparent as the gestation advances,
the majority of the euploid pregnancies having a higher
concentration of fetuin A regardless of gestational week.
4. Discussion
To our knowledge, fetuin A has not previously been studied
in the human amniotic fluid. The composition of amniotic
fluid is similar to that of fetal plasma up to the commence-
ment of keratinization of the fetal skin, which starts at
around 20 weeks and is completed by 25 weeks [11]. The
amniotic fluid serves as an extension of the fetal extracellular
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compartment at least in the first half of the pregnancy. It is
in direct contact with the fetal oropharynx, gastrointestinal
tract, lungs, skin, and urinary system, and therefore the
concentration of a fetal protein in the second trimester am-
niotic fluid is expected to be correlated with fetal serum con-
centration.
Fetuin A is amember of the cystatin “superfamily” of cys-
teine protease inhibitors. It is encoded by the AHSG (alpha-
2-Heremans-Schmid glycoprotein) gene that is located on
chromosome 3. It is mainly produced by hepatocytes and
macrophages and is abundant in the bloodstream and the
bones [5, 12]. Studies have shown that not only the genes
located on the extra 21-chromosome of DS but also some of
the genes located on the rest of the chromosomes demon-
strate an altered expression compared with the euploid
control group [13, 14]. Our biochemical approach revealed
a statistically significant decrease in one of the final products
of genes that is not directly related with chromosome 21. The
exact mechanism via which the over- or underexpression of
genes located on chromosome 21 can potentially affect and
alter the expression of various genes on other chromosomes
is still unclear; however, oxidative stress may play a role [15].
This proposal could be confirmed bymeasuringmRNA levels
of the corresponding gene for fetuin A in amniotic fluid,
and this can be a study which could form the objective of
future research. In addition, since fetuin A, which is mainly
a fetal protein [5], is a well-known negative acute-phase
reactant whose levels decrease as a response to exogenous
or endogenous stimuli [16], the reduced amount of fetuin A
in the amniotic fluid derived from pregnancies with trisomy
21 may indicate important oxidative stress which can lead
to various, as yet unknown, abnormal processes during this
early-midfetal stage.
DS is associated with early symmetrical growth restric-
tion, as opposed to the later onset asymmetrical growth
restriction of intrauterine growth restricted (IUGR) fetuses
[17]. IUGR fetuses have not been found to be associated
with altered fetuin A concentrations but with defects in
glycosylation of fetuin A that possibly alter its function and
potentially lead to fetal growth impairment [18, 19]. In our
study, since we measured the concentration of total fetuin A,
our results indicate that the impaired fetal growth in trisomy
21—which is mainly symmetrical—may be associated with
the reduced total fetuin A production and concentration.
However, it cannot be excluded that the impaired fetal
growth in trisomy 21 may also be attributed to other factors
related to fetuin A, such as a defect in its metabolism or
glycosylation in the early second trimester. The latter issue,
which was beyond the scope of our study, remains a question
to be resolved.
The action of fetuin A has been associated with bone
formation and remodelling [20], and its levels correlate with
the concentration of calcium during bone development [21].
Reduced levels of fetuin A in DS fetuses may have some
association with the impaired bone mineralization during
fetal life which could lead to delayed mineralization of the
nasal bone and short femur or to the reported reduced bone
density and osteoporosis in children and adults with DS [3].
Further studies are needed to elucidate this matter.
Fetuin A has been identified in early differentiating neo-
cortical cells in numerous mammalian species [22, 23].
These animal studies so far tend to indicate that fetuin
may play a significant role in neocortical development.
Dziegielewska et al. have suggested, based on the drop in the
levels of neocortical fetuin along with delivery, that fetuin
may be responsible for early maturation of the initial layers
of neocortex and the survival of cells that undergo apoptosis
as part of the brain development process [22]. Although
fetuin has not been examined in neocortical cells of human
fetuses, postmortem examinations of DS fetuses have shown
smaller neocortical cell numbers, by around one-third, in
DS fetuses at 19 weeks gestation compared to the control
group [24]. The lower levels of fetuin A in amniotic fluid of
DS fetuses may be associated with the impaired development
of the neocortex in these fetuses and with the subsequent
lower mental capacity of children and adults with DS.
5. Conclusion
Our findings support the hypothesis that certain features of
DS may be associated with altered concentrations of fetuin A
in the early 2nd trimester amniotic fluid. Our data, although
limited, could prompt further research into fetuin A and
other proteins related to metabolism in the first half of
pregnancy that should result in a better understanding of
the physiopathological changes associated with DS. However,
we are far from developing in utero treatments that will
regulate factors that are reduced or increased with the aim
of improving the pathological features of DS. Nonetheless,
this approach may be of particular public health importance,
especially in countries or individuals where the termination
of pregnancy for DS is not legal or acceptable.
To our knowledge, this is the first study to measure the
concentration of fetuin A in human amniotic fluid. Although
there are limitations to our study, our data are likely to
contribute to elucidation of the metabolic and inflammatory
pathways in DS that are related to fetuin A from the early
stage of the second trimester. Additional research is required
to further explain the observed difference.
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